<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487577</url>
  </required_header>
  <id_info>
    <org_study_id>CHP_BMT_MMF_10</org_study_id>
    <nct_id>NCT01487577</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention</brief_title>
  <official_title>A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone marrow transplantation (BMT) is used to successfully treat high-risk forms of leukemia,
      lymphoma, and other childhood cancers that were once considered incurable. A major barrier to
      the application of this life-saving treatment is acute graft-versus-host disease (GVHD) which
      develops in approximately 30-80% of patients and is a leading cause of death from transplant
      complications. Current GVHD prevention methods are not very efficacious and lead to
      unacceptable side effects. Mycophenolate mofetil (MMF), an anti-rejection medication used in
      solid organ transplants, has shown great promise in BMT recipients. The effectiveness of MMF
      depends on blood levels of mycophenolic acid (MPA, the active form of MMF). Different
      patients have been found to have different blood levels of MPA when they are given the same
      dose of MMF. The purpose of this study is to study a novel method of giving MMF based on its
      metabolism (pharmacokinetics) to achieve desired blood levels of MPA for prevention of GVHD.
      Non-invasive ways of monitoring the drug exposure will also be studied. The ultimate goal of
      this study is to improve approaches to GVHD prevention and improve outcomes of BMT in
      children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft-versus-host disease (GVHD) remains a major barrier to the success of allogeneic blood
      and marrow transplant (BMT) therapy. Acute GVHD is seen in 30-80% of patients and once
      established, often responds poorly to therapy and is associated with chronic disease and
      increased risk of death. Although combination of methotrexate (MTX) and a calcineurin
      inhibitor has been the &quot;standard of care&quot; for more than a quarter of a century, there is
      little consensus on the most effective and least toxic approach to GVHD prevention. MTX use
      is associated with painful mucositis, delay in engraftment and potential pulmonary toxicity.
      For cord blood transplants, commonly, a calcineurin inhibitor is used with corticosteroids
      and antithymocyte globulin. Steroid therapy is frequently complicated by high rates of
      infection, hyperglycemia and hypertension.

      Mycophenolate mofetil (MMF), whose metabolite mycophenolic acid (MPA) inhibits proliferation
      of lymphocytes, is approved for prevention of organ transplant rejection. MMF in combination
      with CsA is widely used for GVHD prevention in patients receiving reduced-intensity
      conditioning BMT. It has also been successfully used in primary and salvage therapy of acute
      GVHD. In myeloablative transplants, while the GVHD outcomes appear comparable, this regimen
      appears to have superior toxicity profile in comparison to CsA and MTX with faster
      hematopoietic engraftment and reduced severity and duration of mucositis.

      One challenge with MMF use in BMT recipients is a significantly lower MPA exposure in the
      immediate post-conditioning period when compared to organ transplant recipients. This has
      been shown in a number of pharmacokinetics studies including our preliminary data on
      pediatric myeloablative transplants. Low total and unbound MPA trough concentrations are
      associated with higher rates of acute GVHD and graft rejection, and lower response rates in
      treatment of acute GVHD. There is also poor correlation between MPA trough concentration and
      area under the concentration curve (AUC). While most previous studies have used fixed MMF
      dosing, one recent study in adults has shown feasibility of AUC-based individualized MMF
      dosing.

      This protocol is based on the premise that optimization of MPA exposure in the immediate
      post-transplant phase will lead to better acute GVHD prevention. It will study an AUC-based
      targeting of MMF in pediatric patients undergoing myeloablative allogeneic BMT. We propose a
      novel continuous infusion method for MMF administration to achieve total MPA steady state
      concentration. Salient findings emerging from this study will be examined and in replicate
      cohorts of pediatric and adult patients undergoing allo-BMT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade â‰¥3 Toxicities Scored According to the CTCAE Version 4.0.</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Acute Grade II-IV GVHD, Acute Grade III-IV GVHD, and Chronic GVHD.</measure>
    <time_frame>1 year</time_frame>
    <description>Acute GVHD will be graded according to the Modified Glucksberg Staging Criteria. Chronic GVHD will be graded according to NIH Chronic GVHD Consensus Guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutrophil and Platelet Engraftment.</measure>
    <time_frame>100 days</time_frame>
    <description>Neutrophil and platelet engraftment definitions as defined by the CIBMTR Data Management Manual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Relapse.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Nonrelapse Mortality.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Overall Survival.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of MMF AUC to Evaluate MMF Dose Relationships to Drug Exposure.</measure>
    <time_frame>100 days</time_frame>
    <description>Pharmacokinetic analysis includes, but is not limited to, area under the plasma concentration versus time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of MMF Clearance to Evaluate MMF Dose Relationships to Drug Exposure.</measure>
    <time_frame>100 days</time_frame>
    <description>Pharmacokinetic analysis includes, but is not limited to, clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of MMF Steady State Concentration to Evaluate MMF Dose Relationships to Drug Exposure.</measure>
    <time_frame>100 days</time_frame>
    <description>Pharmacokinetic analysis includes, but is not limited to, steady-state concentrations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Allogeneic Blood and Marrow Transplantation (BMT)</condition>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetics-based targeting of mycophenolate mofetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be between 6 months and 21 years of age.

          -  Recipients of an allogeneic blood and marrow transplant (BMT).

          -  Stem cell sources should be bone marrow or umbilical cord blood.

          -  Bone marrow or cord blood unit: Sibling should be HLA matched at A, B and DRB1 loci.
             Unrelated cord blood unit should be at a minimum 4/6 matched at allele level on HLA A,
             B and DRB1 loci. Unrelated donor should be HLA allele level matched at A, B, C and
             DRB1 loci.

          -  Minimum prefreezing nucleated cell dose for cord blood units: 3x10^7/kg for malignant
             diseases and 5x10^7/kg for nonmalignant diseases.

          -  Conditioning regimen must be myeloablative in intensity. Examples include but are not
             limited to Cy/TBI, BuCy 200, etc.

          -  Patients â‰¥ 16 years old must have a Karnofsky score â‰¥ 70%, and patients &lt; 16 years old
             must have a Lansky score â‰¥ 70%.

          -  Renal: Creatinine clearance or radioisotope GFR â‰¥ 70 mL/min/1.73 m2.

          -  Hepatic: Total bilirubin â‰¤ 2.5 mg/dL unless the increase in bilirubin is attributable
             to Gilbert's syndrome; and SGOT (AST), SGPT (ALT), and Alkaline Phosphatase &lt; 5 x
             upper limit of normal (ULN) for age.

          -  Cardiac: Left ventricular ejection fraction at rest &gt; 40%, or shortening fraction &gt;
             26%, by echocardiogram or radionuclide scan.

          -  Pulmonary: FEV1, FVC, and DLCO (diffusion capacity) &gt; 50% of predicted (corrected for
             hemoglobin); if unable to perform pulmonary function tests, then O2 saturation &gt; 92%
             of room air.

        Exclusion Criteria:

          -  Patients with a known hypersensitivity to MMF.

          -  Prior autologous or allogeneic BMT &lt; 12 months prior to enrollment.

          -  Mismatched related donor.

          -  Mismatched unrelated marrow donor.

          -  Peripheral blood stem cell source.

          -  Reduced intensity conditioning.

          -  Uncontrolled bacterial, viral, fungal or other infection.

          -  Evidence of HIV infection or HIV positive serology.

          -  Requirement of supplemental oxygen.

          -  Patients who are pregnant (B-hCG positive) or breastfeeding. All females of 11 years
             of age or older and/or who have begun menstruating will be screened for hCG by either
             urinalysis or a blood sample in order to screen for pregnancy status, as per
             institutional BMT policy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy M Windreich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Pittsburgh of UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <results_first_submitted>February 24, 2016</results_first_submitted>
  <results_first_submitted_qc>May 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2016</results_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Randy Windreich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Allogeneic blood and marrow transplantation (BMT)</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Candidates are identified through the investigators' clinical practice.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mycophenolate Mofetil</title>
          <description>Pharmacokinetics-based targeting of Mycophenolate mofetil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18">One participant became ineligible after signing consent, but before receiving protocol therapy.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Became ineligible after signing consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pediatric hematopoietic stem cell recipients undergoing myeloablative conditioning therapy</population>
      <group_list>
        <group group_id="B1">
          <title>Mycophenolate Mofetil</title>
          <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade â‰¥3 Toxicities Scored According to the CTCAE Version 4.0.</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade â‰¥3 Toxicities Scored According to the CTCAE Version 4.0.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Grade II-IV GVHD, Acute Grade III-IV GVHD, and Chronic GVHD.</title>
        <description>Acute GVHD will be graded according to the Modified Glucksberg Staging Criteria. Chronic GVHD will be graded according to NIH Chronic GVHD Consensus Guidelines.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Grade II-IV GVHD, Acute Grade III-IV GVHD, and Chronic GVHD.</title>
          <description>Acute GVHD will be graded according to the Modified Glucksberg Staging Criteria. Chronic GVHD will be graded according to NIH Chronic GVHD Consensus Guidelines.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute grade II-IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute grade III-IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutrophil and Platelet Engraftment.</title>
        <description>Neutrophil and platelet engraftment definitions as defined by the CIBMTR Data Management Manual.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutrophil and Platelet Engraftment.</title>
          <description>Neutrophil and platelet engraftment definitions as defined by the CIBMTR Data Management Manual.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Incidence of neutrophil engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence of platelet engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Relapse.</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Relapse.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Nonrelapse Mortality.</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Nonrelapse Mortality.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Overall Survival.</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Overall Survival.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis of MMF AUC to Evaluate MMF Dose Relationships to Drug Exposure.</title>
        <description>Pharmacokinetic analysis includes, but is not limited to, area under the plasma concentration versus time curve (AUC).</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Analysis of MMF AUC to Evaluate MMF Dose Relationships to Drug Exposure.</title>
          <description>Pharmacokinetic analysis includes, but is not limited to, area under the plasma concentration versus time curve (AUC).</description>
          <units>mcg*hr/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC, Intermittent IV dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="16.7" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC, Continuous infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="20.6" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC, Intermittent PO dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="11.9" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis of MMF Clearance to Evaluate MMF Dose Relationships to Drug Exposure.</title>
        <description>Pharmacokinetic analysis includes, but is not limited to, clearance.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Analysis of MMF Clearance to Evaluate MMF Dose Relationships to Drug Exposure.</title>
          <description>Pharmacokinetic analysis includes, but is not limited to, clearance.</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance, Intermittent IV dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="6.8" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance, Continuous infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="7.2" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance, Intermittent PO dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="4.9" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis of MMF Steady State Concentration to Evaluate MMF Dose Relationships to Drug Exposure.</title>
        <description>Pharmacokinetic analysis includes, but is not limited to, steady-state concentrations.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Analysis of MMF Steady State Concentration to Evaluate MMF Dose Relationships to Drug Exposure.</title>
          <description>Pharmacokinetic analysis includes, but is not limited to, steady-state concentrations.</description>
          <units>mcg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Steady-state concentration, Intermittent IV dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.6" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Steady-state concentration, Continuous infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.9" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Steady-state concentration, Intermittent PO dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year post-enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mycophenolate Mofetil</title>
          <description>Pharmacokinetics-based targeting of mycophenolate mofetil
Mycophenolate mofetil: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Aseptic pericardial effusion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders, other</sub_title>
                <description>Veno-occlusive disease of the liver</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tracheitis</sub_title>
                <description>Laryngotracheitis due to HSV</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GVHD</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chronic GVHD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study is limited by small sample size and heterogeneity in stem cell sources. Besides targeted MMF dosing, other factors that might have affected clinical outcomes include duration of MMF and use of ATG in unrelated-donor transplants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Randy M. Windreich, MD</name_or_title>
      <organization>Children's Hospital of Pittsburgh of UPMC</organization>
      <phone>412-692-5225</phone>
      <email>randy.windreich@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

